Inospin invites

Technology Transfer Officers & Investigators

to an exclusive webinar with Boehringer Ingelheim’s opnMe team.​

 

Inospin and Boehringer Ingelheim have been collaborating for more than four years on various initiatives that led to multiple collaborations between Boehringer Ingelheim and academic research groups.​ Claudia Heine and Menorca Chaturvedi will present the successful Open Innovation program opnMe.com driven by their team to foster collaboration on innovative scientific project proposals.  ​

​This webinar aims at strengthening the collaboration with academic groups and their Tech Transfer Offices, and also discuss 4 on-going calls for proposals.

This session will include a dedicated Q&A where you will have the chance to submit your questions to the Speakers​.

Do not miss this opportunity as the webinar will not be recorded.

Registration is open to everyone.  Scroll down to register. 

When:

Tuesday, November 16th , 2:00 PM (Central European Time)​ // 8:00 AM (EST)

 

Who should join ?

Technology Transfer professionals 

Investigators working on the topics mentioned below

 

Deep Dive into:

• opnMe.com: ´Molecules to Order´ – Sharing molecules free of charge to foster independent research and publications
• Molecules for Collaboration – Dual Vanin inhibitor│BI-4122: opnMe.com shares a selective and highly potent dual Vanin inhibitor for collaboration that blocks the enzymatic activities of Vanin 1 and 2. Interested scientists are invited to submit testable research proposals that demonstrate utility of Vanin enzymatic activity inhibition in novel disease indications with high unmet medical need. – Research funding available!
• opn2EXPERTS – Elucidate CD73’s potential role in lung injury and repair: Using novel in vitro cellular systems utilizing human patient biopsies, how would you propose to elucidate the role by which CD73 acts on pathologic mechanisms in the context of lung injury and repair? – Access our unique anti-CD73 monoclonal antibody to validate your hypothesis and obtain research funding!
• opn2EXPERTS – Animal Health:
  • Learn about two recently launched questions from the field of Animal Health. However, due to their nature, responses from other fields are welcome!
    • Equine Metabolic Syndrome
    • Canine Oncology
• Questions & Answers

 

Speakers:  ​

Dr. ​Claudia Heine:

​

Dr. Menorca Chaturvedi:

opnMe.com

opnMe.com, the open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, molecules are provided to the scientific community to help unlock and fulfil their full potential.

​These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions as “Molecules for Collaboration”. As part of the third pillar, “opn2EXPERTS” program, Boehringer Ingelheim also enlists scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.​

Through opnMe.com, any researcher can request for probe molecules easily. So far, approximately 3,500 compounds have already been shipped and more than 60 publications have shared insights gathered using these probes. One of the big successes came in last year, when the mystery of the mode of action of BI-3802, a BCL6 degrader, was solved by a group of international researchers (Dana Farber Cancer Research Institute, Broad Institute, Wellcome Sanger Institute). The unique mode of action of this molecule, published in Nature, may pave the way for development of new therapeutic agents and better understanding of the biology of molecular glues.

Register now! 

If the registration form does not display properly. Please follow this link